| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9333270 | ON TARGET LABS | Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors |
Aug, 2033
(9 years from now) | |
| US9341629 | ON TARGET LABS | Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors |
Aug, 2033
(9 years from now) | |
| US9061057 | ON TARGET LABS | Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors |
Aug, 2033
(9 years from now) | |
| US10881747 | ON TARGET LABS | Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors |
Aug, 2033
(9 years from now) | |
| US9789208 | ON TARGET LABS | Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors |
Aug, 2033
(9 years from now) | |
| US9254341 | ON TARGET LABS | Methods of manufacture of pteroyl-amino acid-fluorescent dyes |
Oct, 2033
(9 years from now) | |
Cytalux is owned by On Target Labs.
Cytalux contains Pafolacianine Sodium.
Cytalux has a total of 6 drug patents out of which 0 drug patents have expired.
Cytalux was authorised for market use on 29 November, 2021.
Cytalux is available in solution;intravenous dosage forms.
Cytalux can be used as cytalux is an optical imaging agent indicated in adult patients with ovarian cancer as an adjunct for intraoperative identification of malignant lesions.
Drug patent challenges can be filed against Cytalux from 29 November, 2025.
The generics of Cytalux are possible to be released after 04 October, 2033.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 29, 2026 |
| New Indication(I-905) | Dec 16, 2025 |
| Orphan Drug Exclusivity(ODE-390) | Nov 29, 2028 |
Drugs and Companies using PAFOLACIANINE SODIUM ingredient
NCE-1 date: 29 November, 2025
Market Authorisation Date: 29 November, 2021
Treatment: Cytalux is an optical imaging agent indicated in adult patients with ovarian cancer as an adjunct for intraoperative identification of malignant lesions
Dosage: SOLUTION;INTRAVENOUS
CYTALUX family patents
